The BASAL-BALI study provided real-world effectiveness and safety data suggesting that basal insulin analogues may be the preferred treatment option for persons with T2DM who do not achieve good glycemic control with human insulins. The gene discussed is INS; the disease is type 2 diabetes mellitus.